First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
By nh|2019-06-03T22:18:15+02:00October 26th, 2017|Press release, TG6002|Comments Off on First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
About the Author: nh
